GHB

Gamma-hydroxybutyric acid (GHB) is a naturally occurring substance found in small quantities in the human brain, where it functions as both a neurotransmitter and a neuromodulator. In its synthetic form, GHB occupies a unique position in pharmacology as both a legally prescribed medication and a widely used recreational substance. Under the brand names Xyrem and subsequently Xywav (sodium oxybate), it is an FDA-approved treatment for narcolepsy with cataplexy and excessive daytime sleepiness, administered in tightly controlled clinical settings due to its abuse potential.

Pharmacologically, GHB acts primarily as an agonist at GABA-B receptors, the same receptor system targeted by the muscle relaxant baclofen, though at higher concentrations it also activates a dedicated GHB receptor whose full physiological role remains an area of active research. This dual receptor activity produces dose-dependent effects that range dramatically across the dosing spectrum. At low doses (0.5-1.5 grams), users typically experience mild euphoria, increased sociability, a reduction in social anxiety, and effects often compared to a clean version of alcohol intoxication -- warmth, talkativeness, and physical relaxation without the cognitive cloudiness. At moderate doses (1.5-2.5 grams), the euphoria intensifies, music and physical touch become enhanced, and a distinctive pro-sexual effect emerges that has made GHB particularly popular in certain nightlife and chemsex contexts. At high doses (2.5 grams and above), sedation rapidly overtakes stimulation, and the narrow window between a strong recreational dose and unconsciousness becomes dangerously thin.

This extraordinarily steep dose-response curve is the defining danger of GHB. The difference between a dose that produces pleasant euphoria and one that causes deep unconsciousness from which a person cannot be roused may be as little as half a gram -- a quantity nearly impossible to measure accurately with improvised tools. The substance is most commonly encountered as a clear, slightly salty liquid of unknown concentration, making consistent dosing a persistent challenge even for experienced users. GHB-induced unconsciousness can progress to respiratory depression, vomiting while unconscious (with aspiration risk), and in severe cases, coma or death.

The danger profile is sharply compounded by combining GHB with other central nervous system depressants. Alcohol and GHB together produce synergistic respiratory depression that has been responsible for the majority of GHB-related fatalities. Even a single alcoholic drink can dramatically lower the threshold for GHB overdose. Benzodiazepines and opioids carry the same risk. Anyone choosing to use GHB must understand that polydrug combinations involving other depressants are genuinely life-threatening, not merely inadvisable. Accurate volumetric dosing with a measured syringe, starting with small amounts of any new batch, and absolute avoidance of alcohol and other depressants represent the minimum standards for harm reduction with this substance.